Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

Patients with non–small-cell lung cancer were randomly assigned to three cycles of chemotherapy with or without nivolumab, an anti–PD-1 antibody. Event-free survival was longer with nivolumab than without it (31.6 months vs. 20.8 months), and the percentage of patients with a pathological complete r...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2022-05, Vol.386 (21), p.1973-1985
Hauptverfasser:	Forde, Patrick M., Spicer, Jonathan, Lu, Shun, Provencio, Mariano, Mitsudomi, Tetsuya, Awad, Mark M., Felip, Enriqueta, Broderick, Stephen R., Brahmer, Julie R., Swanson, Scott J., Kerr, Keith, Wang, Changli, Ciuleanu, Tudor-Eliade, Saylors, Gene B., Tanaka, Fumihiro, Ito, Hiroyuki, Chen, Ke-Neng, Liberman, Moishe, Vokes, Everett E., Taube, Janis M., Dorange, Cecile, Cai, Junliang, Fiore, Joseph, Jarkowski, Anthony, Balli, David, Sausen, Mark, Pandya, Dimple, Calvet, Christophe Y., Girard, Nicolas
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Antineoplastic Agents, Immunological - adverse effects Antineoplastic Agents, Immunological - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - surgery Chemotherapy Clinical medicine Clinical trials Committees Critical Care Critical Care General Hematology Humans Hypothesis testing Immunotherapy Ipilimumab - adverse effects Lung Cancer Lung Neoplasms - drug therapy Lung Neoplasms - surgery Lymph nodes Lymphatic system Medical prognosis Monoclonal antibodies Neoadjuvant Therapy Neoplasm Recurrence, Local - drug therapy Nivolumab - adverse effects Nivolumab - therapeutic use Non-small cell lung carcinoma Oncology Patients Platinum Platinum Compounds - adverse effects Platinum Compounds - therapeutic use Pulmonary Small cell lung carcinoma Surgery Targeted cancer therapy Treatments in Oncology Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Patients with non–small-cell lung cancer were randomly assigned to three cycles of chemotherapy with or without nivolumab, an anti–PD-1 antibody. Event-free survival was longer with nivolumab than without it (31.6 months vs. 20.8 months), and the percentage of patients with a pathological complete response was 24.0% and 2.2%, respectively.
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa2202170